

Title (en)

Crystalline or crystallized acid addition salt of losartan and purification method of losartan

Title (de)

Kristallines oder kristallisiertes Säureadditionssalz von Losartan und Verfahren zur Reinigung von Losartan

Title (fr)

Sels cristallins ou cristallisés d'acide d'addition de losartane et procédé pour la purification de losartane

Publication

EP 1106611 A1 20010613 (EN)

Application

EP 00126032 A 20001129

Priority

- JP 34682999 A 19991206
- JP 2000282853 A 20000919

Abstract (en)

The present invention provides a crystalline or crystallized acid addition salt of Losartan useful for obtaining highly pure 2-n-butyl-4-chloro-1- H -tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl-1H-imidazole-5-methanol (Losartan), and a purification method of Losartan that includes production of the crystalline or crystallized acid addition salt.

IPC 1-7

C07D 403/10

IPC 8 full level

A61K 31/4178 (2006.01); **A61P 43/00** (2006.01); **C07D 403/10** (2006.01)

CPC (source: EP US)

A61P 43/00 (2018.01 - EP); **C07D 403/10** (2013.01 - EP US)

Citation (search report)

- [DX] WO 9310106 A1 19930527 - DU PONT [US], et al
- [AD] WO 9517396 A1 19950629 - MERCK & CO INC [US], et al
- [A] WO 9818787 A1 19980507 - MERCK & CO INC [US], et al

Cited by

WO2004066997A3

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

EP 1106611 A1 20010613; **EP 1106611 B1 20040623**; AT E269858 T1 20040715; DE 60011739 D1 20040729; DE 60011739 T2 20050901; ES 2218051 T3 20041116; JP 2001226372 A 20010821; US 6350880 B1 20020226

DOCDB simple family (application)

EP 00126032 A 20001129; AT 00126032 T 20001129; DE 60011739 T 20001129; ES 00126032 T 20001129; JP 2000282853 A 20000919; US 71433900 A 20001116